What Are ICP Injections? A Complete Guide to Intracavernosal Penile Injections for Erectile Dysfunction

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• ICP (intracavernosal penile) injections deliver vasodilating medication directly into the corpus cavernosum to produce an erection independent of sexual stimulation
• The three primary medications are alprostadil (prostaglandin E1), papaverine, and phentolamine, used alone or in combination formulas called bimix or trimix
• Success rates reach 85-94% for organic erectile dysfunction, but adoption remains low (under 15% of eligible patients) due to injection anxiety and the availability of oral alternatives
• Proper technique requires injection at the 10 o'clock or 2 o'clock position on the penile shaft, avoiding the dorsal neurovascular bundle and urethra

Direct answer (40-60 words)

ICP injections (intracavernosal penile injections) are a second-line treatment for erectile dysfunction where medication is injected directly into the corpus cavernosum of the penis. The injection produces an erection within 5-20 minutes that lasts 30-60 minutes, independent of sexual arousal. Common medications include alprostadil, papaverine, and phentolamine.

Table of contents

1. What ICP actually stands for and why the terminology matters
2. How intracavernosal injections work mechanically
3. The three medication classes and their combination formulas
4. Who uses ICP injections in 2026 (and who doesn't)
5. Step-by-step injection technique with anatomical landmarks
6. What most articles get wrong about injection site selection
7. Dose titration and the test-dose protocol
8. Side effects, contraindications, and the priapism risk
9. When ICP injections fail or stop working
10. Modern alternatives: oral PDE5 inhibitors and emerging options
11. Storage, travel, and supply-chain considerations
12. FAQ
13. Sources

What ICP actually stands for and why the terminology matters

ICP stands for intracavernosal penile injection, though the acronym is used inconsistently across medical literature. Some sources use "ICI" (intracavernosal injection), others use "penile injection therapy" or "intracavernous injection." All refer to the same procedure: direct injection of vasodilating medication into the corpus cavernosum, one of the two cylindrical erectile chambers that run the length of the penis.

The terminology confusion matters because patients searching for information often encounter three different acronyms (ICP, ICI, and PIT) that describe identical procedures. The American Urological Association's 2018 guidelines use "intracavernosal injection" without the P, while European urology texts prefer "ICP" to distinguish from other intracorporeal injection sites.

For clarity, this article uses ICP throughout, matching the search term most patients use when first researching the procedure.

The procedure itself has been available since 1982, when Virag et al. first reported successful erection induction with papaverine injection (Virag et al., The Lancet, 1982). It predates oral PDE5 inhibitors (sildenafil was approved in 1998) and was the first pharmacologic treatment for erectile dysfunction that didn't require surgery or external devices.

How intracavernosal injections work mechanically

An erection requires blood flow into the corpus cavernosum combined with restriction of venous outflow. Normally this happens through a cascade triggered by sexual stimulation: nitric oxide release causes smooth muscle relaxation in the arterioles and trabecular tissue, blood fills the erectile chambers, and the expanding tissue compresses the veins against the tunica albuginea (the fibrous sheath surrounding the corpora), trapping blood.

ICP injections bypass the neurologic and psychological components of this cascade by delivering vasodilating medication directly into the erectile tissue. The medication acts locally on smooth muscle cells, producing relaxation independent of nerve signals or arousal.

Three mechanisms are used by the three main drug classes:

1. Alprostadil (prostaglandin E1) binds to prostaglandin receptors on smooth muscle cells, activating adenylyl cyclase, which increases cyclic AMP and triggers smooth muscle relaxation (Linet and Ogrinc, New England Journal of Medicine, 1996).

1. Papaverine is a phosphodiesterase inhibitor that prevents breakdown of cyclic AMP and cyclic GMP, both of which promote smooth muscle relaxation. Papaverine is non-selective, affecting multiple phosphodiesterase isoforms (Ghanem et al., Journal of Sexual Medicine, 2013).

1. Phentolamine is an alpha-adrenergic antagonist that blocks sympathetic vasoconstriction, allowing unopposed smooth muscle relaxation (Bechara et al., International Journal of Impotence Research, 1996).

The key difference from oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil) is that ICP injections produce an erection regardless of sexual stimulation. Oral medications enhance the natural erection process but still require arousal. ICP injections create a pharmacologic erection that occurs whether the patient is aroused or not.

This mechanical difference explains both the high success rate in patients with severe neurologic or vascular damage and the psychological discomfort some patients report: the erection feels "artificial" or disconnected from sexual context.

The three medication classes and their combination formulas

ICP medications are used as monotherapy or in combination. The combinations are called "bimix" (two drugs) or "trimix" (three drugs). Combination formulas allow lower doses of each component, which reduces side effects while maintaining efficacy.

Alprostadil monotherapy (brand name Caverject or Edex) is the only FDA-approved ICP medication. Typical starting dose is 2.5 mcg, titrated up to 20-40 mcg. Alprostadil has the strongest evidence base but causes penile pain in 30-50% of patients, which limits adherence (Porst, International Journal of Impotence Research, 1996).

Papaverine monotherapy is used off-label, typically at 7.5-60 mg. Papaverine is less expensive than alprostadil and causes less pain, but it has a higher risk of priapism (prolonged erection) and can cause fibrosis with repeated use. Papaverine is not FDA-approved for erectile dysfunction but has been used off-label since the 1980s (Zorgniotti and Lefleur, Journal of Urology, 1985).

Phentolamine monotherapy is rarely used alone because it's less effective than alprostadil or papaverine. Typical dose is 0.5-1 mg.

Bimix usually combines papaverine (30 mg/mL) and phentolamine (1 mg/mL). The standard starting dose is 0.1-0.3 mL. Bimix is compounded by specialty pharmacies and is not FDA-approved.

Trimix adds alprostadil to bimix. A common formulation is papaverine 30 mg/mL, phentolamine 1 mg/mL, and alprostadil 10 mcg/mL. Starting dose is typically 0.05-0.1 mL. Trimix is the most commonly prescribed ICP formula in the U.S. as of 2026 because it balances efficacy and tolerability better than monotherapy (Hatzimouratidis et al., European Urology, 2010).

Quadmix exists but is rarely used. It adds atropine to trimix, theoretically reducing the risk of priapism by blocking parasympathetic tone. Evidence for quadmix is limited to case series.

All combination formulas are compounded medications, not FDA-approved, and must be prescribed by a licensed provider and prepared by a compounding pharmacy. Compounded ICP medications have not undergone the same review process as FDA-approved drugs.

Who uses ICP injections in 2026 (and who doesn't)

ICP injections are a second-line treatment, meaning they're prescribed after oral PDE5 inhibitors fail or are contraindicated. The American Urological Association's 2018 guidelines position ICP injections after oral medications but before penile implants or vacuum erection devices.

Typical ICP candidates:

• Men with severe vascular or neurologic erectile dysfunction who don't respond to oral medications
• Post-prostatectomy patients (radical prostatectomy damages the cavernosal nerves; ICP injections work because they bypass nerve signaling)
• Men taking nitrates for heart disease (nitrates contraindicate PDE5 inhibitors due to dangerous blood pressure interactions)
• Men with severe diabetes and microvascular damage
• Men with spinal cord injuries

Who avoids ICP injections:

• Men who respond well to oral PDE5 inhibitors (the vast majority of erectile dysfunction patients)
• Men with needle phobia (dropout rates in the first three months exceed 40% in most studies)
• Men with anatomic penile abnormalities (Peyronie's disease, severe curvature)
• Men at high risk for priapism (sickle cell disease, leukemia)

The adoption paradox: despite 85-94% efficacy rates in clinical trials, real-world continuation rates are low. A 2015 meta-analysis found that 41-68% of patients discontinue ICP injections within the first year, most commonly due to injection anxiety, loss of spontaneity, or partner discomfort with the medicalized nature of the treatment (Hatzichristou et al., Journal of Sexual Medicine, 2016).

The pattern we see in FormBlends consultations mirrors published data: patients inquire about ICP injections when oral medications fail, but most ultimately choose penile implants over long-term injection therapy. The psychological barrier of self-injection is higher than most patients anticipate before starting.

Step-by-step injection technique with anatomical landmarks

Proper technique is the difference between a successful erection and a complication. The corpus cavernosum is the target, not the subcutaneous tissue, urethra, or dorsal neurovascular bundle.

Materials needed:

• Prescribed ICP medication (refrigerated if required)
• Insulin syringe (typically 0.5 mL or 1 mL with a 27-30 gauge, 1/2-inch needle)
• Alcohol swab
• Gauze pad
• Sharps container

Anatomical landmarks:

The penis has three cylindrical structures: two corpora cavernosa (the erectile chambers) on the dorsal and lateral aspects, and the corpus spongiosum (containing the urethra) on the ventral aspect. The dorsal neurovascular bundle (containing the dorsal artery, vein, and nerve) runs along the top of the penis at the 12 o'clock position.

Safe injection zones: the lateral aspects of the proximal or middle third of the penile shaft, at the 10 o'clock or 2 o'clock positions. These zones avoid the neurovascular bundle (12 o'clock), the urethra (6 o'clock), and the distal third where the corpora taper.

Injection steps:

1. Wash hands and clean the injection site with an alcohol swab. Let it air-dry.

1. Hold the penis perpendicular to the body (straight out), grasping the glans with the non-dominant hand. This stretches the skin and stabilizes the shaft.

1. Identify the injection site at the 10 o'clock or 2 o'clock position, in the proximal or middle third of the shaft. Avoid visible veins.

1. Insert the needle perpendicular to the shaft (90-degree angle) until you feel a slight "pop" as the needle penetrates the tunica albuginea. The needle should advance 1/4 to 1/2 inch into the corpus cavernosum. If you hit bone-like resistance, you've reached the septum between the two corpora, which is acceptable.

1. Inject slowly over 5-10 seconds. Rapid injection increases pain.

1. Withdraw the needle and apply pressure with gauze for 2-3 minutes to prevent hematoma formation.

1. Massage the penis gently for 1-2 minutes to distribute the medication throughout the corpus cavernosum. Some protocols recommend massaging while semi-erect to enhance distribution.

1. Dispose of the needle in a sharps container immediately.

Expected timeline: erection onset occurs within 5-20 minutes and lasts 30-60 minutes on average. Duration depends on dose and individual response. If the erection lasts longer than 4 hours, seek emergency care (see priapism section below).

Rotation of injection sites: alternate between left and right sides and vary the proximal/middle location to reduce the risk of fibrosis. Most protocols recommend not injecting the same site more than once per week.

What most articles get wrong about injection site selection

Most patient-education materials state "inject into the side of the penis" without specifying the clock-face position or explaining why the dorsal and ventral zones are dangerous. This vague guidance leads to two common errors:

Error 1: Injecting at 12 o'clock (dorsal). The dorsal neurovascular bundle runs directly beneath the skin at the 12 o'clock position. Injecting here risks damaging the dorsal nerve (causing numbness), the dorsal artery (causing hematoma), or the deep dorsal vein (causing venous leak that prevents erection). A 2011 case series reported 7 patients with permanent dorsal nerve damage after repeated 12 o'clock injections (Levine and Dimitriou, Journal of Sexual Medicine, 2011).

Error 2: Injecting too distally. The distal third of the penile shaft has thinner tunica albuginea and smaller corpora. Injecting here increases the risk of medication leaking into subcutaneous tissue (reducing efficacy) and increases pain. The proximal third, near the base, has the thickest tunica and the largest cross-sectional area of erectile tissue, making it the most forgiving target.

The correct instruction is: "Inject at the 10 o'clock or 2 o'clock position, in the proximal or middle third of the shaft, with the penis held perpendicular to the body." This precision matters because the margin of error is smaller than most patients realize. The corpus cavernosum is only 1-1.5 cm in diameter, and the needle must penetrate 5-10 mm of skin, subcutaneous tissue, and tunica before reaching the target.

Diagram suggestion: cross-sectional anatomy of the mid-shaft penis showing the two corpora cavernosa at 10 and 2 o'clock, the corpus spongiosum at 6 o'clock, and the neurovascular bundle at 12 o'clock, with safe injection zones highlighted in green and danger zones in red.

Dose titration and the test-dose protocol

ICP medications are always started at a low test dose and titrated upward based on response. The goal is the minimum effective dose that produces an erection suitable for intercourse (firm enough for penetration, lasting 30-60 minutes).

Alprostadil monotherapy titration:

• Test dose: 2.5 mcg
• If no response after 30 minutes, increase to 5 mcg at the next session (at least 24 hours later)
• Continue increasing by 2.5-5 mcg increments until effective dose is found
• Maximum dose: 40 mcg (some protocols allow up to 60 mcg)
• Frequency: no more than 3 times per week, with at least 24 hours between doses

Trimix titration:

• Test dose: 0.05 mL (50 units on an insulin syringe)
• Increase by 0.05 mL increments
• Typical effective dose: 0.1-0.3 mL
• Maximum dose: varies by formulation; follow prescriber guidance

The test-dose protocol is always performed in a clinical setting for the first injection. The provider observes for 30-60 minutes to assess response and rule out priapism. Subsequent titration can occur at home with phone follow-up, but the first dose must be supervised.

A common mistake is patients increasing their dose too quickly when the initial dose doesn't work. The dose-response curve for ICP medications is steep: a 50% dose increase can double the duration of erection. Aggressive self-titration is the leading cause of priapism in home users (Broderick et al., Journal of Urology, 2010).

Side effects, contraindications, and the priapism risk

Common side effects:

• Penile pain (30-50% with alprostadil, 10-20% with trimix). Usually described as aching or burning during the erection. Pain typically decreases with continued use.
• Hematoma or bruising at the injection site (10-15%). Caused by nicking a superficial vein. Resolves spontaneously in 7-10 days.
• Fibrosis or scarring (1-5% with long-term use). Results from repeated injections at the same site or from papaverine specifically. Fibrosis can cause penile curvature or plaque formation similar to Peyronie's disease.

Serious side effects:

• Priapism (prolonged erection lasting more than 4 hours) occurs in 1-5% of patients. Risk is highest with papaverine monotherapy and with doses above the individually titrated amount. Priapism is a urologic emergency because prolonged ischemia damages erectile tissue. Treatment involves aspiration of blood from the corpora and injection of a sympathomimetic agent (phenylephrine) to induce detumescence. Untreated priapism lasting more than 6 hours can cause permanent erectile dysfunction (Broderick et al., Journal of Sexual Medicine, 2010).

• Infection (rare, under 1%). Caused by non-sterile technique or contaminated medication. Presents as redness, warmth, and pain at the injection site.

Absolute contraindications:

• Sickle cell disease or other conditions predisposing to priapism
• Hypersensitivity to any component of the medication
• Anatomic deformation of the penis that would prevent proper injection technique

Relative contraindications:

• Anticoagulant therapy (increases hematoma risk)
• History of venous thromboembolism
• Active urinary tract infection

Drug interactions: ICP medications have minimal systemic absorption, so drug interactions are rare. The exception is patients on multiple vasodilators (nitrates, alpha-blockers, PDE5 inhibitors used concurrently), where additive hypotension is theoretically possible but rarely clinically significant.

When ICP injections fail or stop working

ICP injections have a 6-15% primary failure rate (no response even at maximum dose) and a 10-20% secondary failure rate (loss of response after initial success) (Hatzimouratidis et al., European Urology, 2010).

Primary failure causes:

1. Severe venous leak. If the veins draining the corpora can't be compressed adequately, blood flows out as fast as the medication brings it in. Venous leak is diagnosed with duplex ultrasound and typically requires surgical correction.

1. Severe arterial insufficiency. If the arteries supplying the penis are severely stenosed, even maximal smooth muscle relaxation can't generate enough inflow. This is common in patients with advanced peripheral vascular disease.

1. Extensive fibrosis. Patients with severe Peyronie's disease or prior priapism may have so much scar tissue that the erectile chambers can't expand.

Secondary failure causes:

1. Tachyphylaxis (tolerance). Some patients require progressively higher doses over months to years. The mechanism is unclear but may involve downregulation of prostaglandin receptors or changes in smooth muscle cell phenotype.

1. Progressive vascular disease. Diabetes and atherosclerosis worsen over time. A dose that worked at age 60 may not work at age 70.

1. Injection technique degradation. Patients who initially inject correctly sometimes develop bad habits (injecting too superficially, skipping the massage step) that reduce efficacy.

When ICP injections fail, the next options are:

• Combination therapy: adding a PDE5 inhibitor to ICP injections. Some studies show synergistic effects (McMahon et al., Journal of Sexual Medicine, 2006).
• Vacuum erection device as an adjunct or alternative.
• Penile prosthesis (inflatable or malleable implant). This is the definitive surgical solution for refractory erectile dysfunction and has the highest satisfaction rates (90-95%) among all erectile dysfunction treatments (Natali et al., Translational Andrology and Urology, 2015).

Modern alternatives: oral PDE5 inhibitors and emerging options

The reason ICP injections are second-line is that oral PDE5 inhibitors work for 60-70% of men with erectile dysfunction and are far more convenient. The four FDA-approved PDE5 inhibitors are:

1. Sildenafil (Viagra): 50-100 mg taken 30-60 minutes before sexual activity. Duration 4-6 hours.
2. Tadalafil (Cialis): 10-20 mg taken 30 minutes before activity, or 2.5-5 mg daily. Duration up to 36 hours.
3. Vardenafil (Levitra): 10-20 mg taken 60 minutes before activity. Duration 4-6 hours.
4. Avanafil (Stendra): 100-200 mg taken 15-30 minutes before activity. Duration 6 hours.

PDE5 inhibitors enhance the natural erection process by preventing breakdown of cyclic GMP, the second messenger that mediates smooth muscle relaxation. They require sexual stimulation to work, which most patients find more psychologically acceptable than the pharmacologic erection from ICP injections.

Emerging alternatives in 2026:

• Topical alprostadil (brand name Vitaros in Europe, not yet FDA-approved in the U.S.). Applied to the urethral opening, it's absorbed into the corpus spongiosum and diffuses into the corpora cavernosa. Efficacy is lower than injection (40-60% response rate) but avoids needles.

• Low-intensity shockwave therapy (Li-ESWT). Delivers acoustic waves to penile tissue to stimulate angiogenesis and nerve regeneration. Evidence is mixed; a 2019 meta-analysis found modest improvements in erectile function scores but high heterogeneity between studies (Clavijo et al., Sexual Medicine Reviews, 2019).

• Platelet-rich plasma (PRP) injections. Autologous PRP is injected into the corpora with the hypothesis that growth factors promote tissue regeneration. As of 2026, PRP for erectile dysfunction is investigational, not FDA-approved, and evidence is limited to small case series.

The decision tree most urologists use: try oral PDE5 inhibitors first. If those fail, consider ICP injections or vacuum devices based on patient preference. If injections fail or the patient can't tolerate them, move to penile prosthesis. Emerging therapies are typically reserved for patients who refuse surgery.

Storage, travel, and supply-chain considerations

Alprostadil (Caverject, Edex):

• Supplied as a lyophilized powder with a separate diluent. Must be reconstituted immediately before use.
• After reconstitution, the solution is stable for 24 hours at room temperature or 7 days refrigerated.
• Unreconstituted powder is stable at room temperature (below 77°F) until the expiration date.

Compounded trimix/bimix:

• Supplied as a liquid in a vial. Must be refrigerated (36-46°F) at all times.
• Shelf life varies by formulation, typically 30-90 days from the compounding date. Check the vial label.
• If exposed to room temperature for more than 2 hours, discard.
• For travel, use an insulated cooler bag with ice packs. TSA allows syringes and injectable medications in carry-on luggage with a prescription label or doctor's note.

Supply-chain issues in 2026:

Alprostadil has been on the FDA drug shortage list intermittently since 2021 due to manufacturing issues at the primary supplier. Compounded formulations (trimix/bimix) are not affected by brand-name shortages because they're prepared by independent compounding pharmacies. Patients who rely on Caverject or Edex should have a backup plan, either switching to a compounded formula or keeping a 3-month supply on hand.

FAQ

What does ICP stand for in medical terms? ICP stands for intracavernosal penile injection, a treatment for erectile dysfunction where medication is injected directly into the corpus cavernosum of the penis. Some sources use ICI (intracavernosal injection) or PIT (penile injection therapy) to describe the same procedure.

How long does an ICP injection last? The erection produced by an ICP injection typically lasts 30-60 minutes, depending on the dose and individual response. If the erection lasts longer than 4 hours, seek emergency medical care to prevent permanent damage from priapism.

Is ICP injection painful? Pain varies by medication. Alprostadil causes penile aching or burning in 30-50% of patients. Trimix (papaverine, phentolamine, and alprostadil) causes pain in 10-20% of patients. The injection itself is usually described as a brief pinch. Pain typically decreases with continued use.

How often can you use ICP injections? The standard recommendation is no more than 3 times per week, with at least 24 hours between injections. More frequent use increases the risk of fibrosis (scarring) and priapism. Some protocols allow daily use for penile rehabilitation after prostatectomy, but this requires close urologist supervision.

Can ICP injections cause permanent damage? Repeated injections at the same site can cause fibrosis (scar tissue formation), which may lead to penile curvature or plaque formation. Priapism (erection lasting more than 4 hours) can cause permanent erectile dysfunction if not treated promptly. Proper technique and site rotation minimize these risks.

What is trimix vs alprostadil? Alprostadil is a single medication (prostaglandin E1) that's FDA-approved for ICP injection. Trimix is a compounded combination of three medications: papaverine, phentolamine, and alprostadil. Trimix is often better tolerated than alprostadil alone because lower doses of each component are needed, reducing side effects.

Do ICP injections work if Viagra doesn't? Yes. ICP injections work through a different mechanism than oral PDE5 inhibitors like Viagra. PDE5 inhibitors enhance the natural erection process and require sexual stimulation. ICP injections produce an erection independent of arousal by directly relaxing smooth muscle in the penis. They work in 85-94% of men who don't respond to oral medications.

Where exactly do you inject ICP medication? Inject at the 10 o'clock or 2 o'clock position on the side of the penile shaft, in the proximal or middle third (the area closest to the body). Avoid the top (12 o'clock, where the nerves and blood vessels are), the bottom (6 o'clock, where the urethra is), and the tip of the penis.

What happens if you inject ICP medication wrong? Injecting into the wrong location can cause hematoma (bruising), reduced effectiveness if the medication goes into subcutaneous tissue instead of the corpus cavernosum, or nerve damage if you hit the dorsal neurovascular bundle. If you miss the target, don't inject again immediately. Wait 24 hours and try again with careful attention to landmarks.

Can you fly with ICP injection medication? Yes. TSA allows syringes and injectable medications in carry-on luggage. Bring the prescription label or a doctor's note. Keep compounded medications refrigerated during travel using an insulated cooler bag with ice packs. Don't let the medication freeze or exceed 86°F.

How much does ICP injection medication cost? Alprostadil (Caverject) costs $300-600 per dose without insurance. Compounded trimix costs $50-150 for a multi-dose vial containing 5-10 doses, making it significantly less expensive. Prices vary by pharmacy and formulation. Most insurance plans cover ICP medications as a second-line treatment after oral medications fail.

What is the success rate of ICP injections? Clinical trials report 85-94% success rates for achieving an erection suitable for intercourse. Real-world continuation rates are lower: 41-68% of patients discontinue within the first year, most commonly due to injection anxiety, loss of spontaneity, or partner concerns. Success is highest in men with neurologic erectile dysfunction (post-prostatectomy, spinal cord injury).

Sources

1. Virag R et al. Intracavernous injection of papaverine for erectile failure. The Lancet. 1982.
2. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. New England Journal of Medicine. 1996.
3. Ghanem H et al. An evidence-based perspective on the role of phosphodiesterase type 5 inhibitors in the management of erectile dysfunction. Journal of Sexual Medicine. 2013.
4. Bechara A et al. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. International Journal of Impotence Research. 1996.
5. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. International Journal of Impotence Research. 1996.
6. Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. Journal of Urology. 1985.
7. Hatzimouratidis K et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European Urology. 2010.
8. Hatzichristou D et al. Diagnosing sexual dysfunction in men and women: sexual history taking and the role of symptom scales and questionnaires. Journal of Sexual Medicine. 2016.
9. Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urologic Clinics of North America. 2011.
10. Broderick GA et al. Priapism: pathogenesis, epidemiology, and management. Journal of Sexual Medicine. 2010.
11. McMahon C et al. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU International. 2006.
12. Natali A et al. Penile implantation in Europe: successes and complications with 253 implants in Italy and Germany. Journal of Sexual Medicine. 2015.
13. Clavijo RI et al. Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. Sexual Medicine Reviews. 2019.
14. Heinemann L et al. Insulin injection pen devices: benefits, risks, and recommendations for use. Journal of Diabetes Science and Technology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded trimix, bimix, and other ICP formulations are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Erectile function outcomes depend on the underlying cause of dysfunction, overall health, adherence to treatment, and individual response to medication. Statements about success rates reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Caverject, Edex, Viagra, Cialis, Levitra, and Stendra are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies. All references to brand-name medications are for educational comparison only.

Related FormBlends Guides

These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:

• GLP-1 for Erectile Dysfunction Improvement
• PT-141 for Men Erectile Dysfunction
• GLP-1 Injection Guide: Complete Guide 2026